X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Biotechnology

Healthcare
$2.98 +1.49%

+$0.06 today

Market cap
$304.30M
Beta
0.37
P/E (TTM)
-5.2
EPS (TTM)
-$0.79
52W Low $1.35High $4.83

Volume 0.64M

Average 0.40M

XFOR Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

X4 Pharmaceuticals, Inc.NASDAQ: XFOR

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$541K, compared with $561K a year earlier. Trailing-twelve-month accounts receivables was -$605K.

Context

  • Accounts receivables amounted to 1.4% of revenue in FY2025, down 40.4 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -$541K or moves back toward the trailing-twelve-month quarterly average of -$151.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$541K-270.1% QoQ
Last fiscal yearDec 2025
$497K+146.4% YoY
LTMMar 2026
-$605K-207.8% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-196.4%——
1 year+146.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
497K USD
Year-over-year change
+146.4%

Accounts Receivables vs competitors

How XFOR compares with its peers on the latest reported figures

  • XFOR's LTM Mar 2026 accounts receivables of $605K is the 3rd largest of the 4 companies compared; the peer median is $646K.
  • Its year-over-year change of -207.8% is the lowest of 3, against a peer median of +168.2%.
  • Accounts receivables amounts to 6.7% of revenue for XFOR, versus a peer median of 7.9%.
XFOR Competitors Peer median
Accounts Receivables for XFOR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$11.89M +385.7%—7.9%
INMBINmune Bio, Inc.LTM Mar 2026$646K -49.3%+1.9%—
XFORX4 Pharmaceuticals, Inc.LTM Mar 2026$605K -207.8%—6.7%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding XFOR) $646K+168.2%+1.9%7.9%

Competitors are the stored peer set for XFOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(88.7M)(93.87M)(101.17M)(37.45M)(79.2M)
Depreciation & Amortization1.89M513K419K796K1.28M
Deferred Income Tax00000
Stock-Based Compensation05.2M8.69M8.2M4.3M
Change in Working Capital(1.5M)5.74M344K2.68M(2.58M)
Accounts Receivables000(1.07M)497K
Inventory000(2.82M)(1.66M)
Accounts Payables1.17M3.43M1.23M(286K)(2.98M)
Other Working Capital(2.66M)2.31M(890K)6.85M1.57M
Other Non-Cash Items17.4M5.32M(4.8M)(105.13M)(9.42M)
Operating Cash Flow(70.91M)(77.1M)(96.51M)(130.9M)(85.62M)
Capital Expenditures(615K)(103K)(60K)(7.33M)(3M)
Acquisitions (Net)00000
Purchases of Investments00(16.82M)(57.13M)(63.39M)
Sales of Investments002M26.45M74.54M
Other Investing Activities00098M0
Investing Cash Flow(615K)(103K)(14.88M)66.99M8.15M
Debt Repayment0(795K)20.44M20M0
Common Stock Issued76.25M122.63M60M294K238.53M
Common Stock Repurchased(2M)0000
Dividends Paid00000
Other Financing Activities0(4.61M)8.08M098K
Financing Cash Flow74.25M117.23M88.52M20.29M238.63M
Effect of Forex Changes90K(105K)99K(156K)213K
Net Change in Cash2.82M39.92M(22.78M)(43.77M)161.38M
Free Cash Flow(71.52M)(77.21M)(96.57M)(138.23M)(88.62M)

X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Intrinsic Alpha fair value

Locked

Current Price

$2.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.